Non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) are worldwide
public health problems, affecting up to 25–30%(NAFLD), and up to 10–15%(CKD) of the …

Hypertension, a multifactorial disorder resulting from the interplay between genetic
predisposition and environmental risk factors, affects≈ 30% of adults. Emerging evidence …

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …

Background With the rising global prevalence of fatty liver disease related to metabolic
dysfunction, the association of this common liver condition with chronic kidney disease …

Background & Aims The LIVIFY trial investigated the safety, tolerability, and efficacy of
vonafexor, a second-generation, non-bile acid farnesoid X receptor agonist in patients with …

Since the implementation of the Model of End-stage Liver Disease score-based allocation
system, the number of transplant candidates with impaired renal function has increased. The …

Abstract Background and Aim Non‐alcoholic fatty liver disease (NAFLD) is a multisystem
disease associated with an increased risk of cardiovascular disease (CVD), diabetes, and …

Background and aim Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic
liver disease. Its role in the development of extrahepatic co-morbidities is under …

Accumulating evidence now indicates that non-alcoholic fatty liver disease (NAFLD), which
is the most common chronic liver disease observed in clinical practice worldwide, is …

Background As the prevalence of nonalcoholic fatty liver disease (NAFLD) escalates,
understanding its potential impact on the development of chronic kidney disease (CKD) is …